Letter to the EditorShould we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?☆
Section snippets
Acknowledgement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
We thank internal medicine physicians for their help in collecting the clinical data (M.Ebbo, N.Schleinitz, G.Kaplanski, C.Gomez).
References (10)
- et al.
Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma
Eur J Intern Med
(2010) - et al.
Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis
J Clin Invest
(1993) - et al.
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Arthritis Rheum
(2013) - et al.
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis
Arthritis Rheumatol Hoboken NJ
(2014) - et al.
Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
Rheumatol Oxf Engl
(2008)
There are more references available in the full text version of this article.
Cited by (3)
Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: Multicentric Study from Argentina
2022, Reumatologia ClinicaThe clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: Results from the EUSTAR cohort
2021, Rheumatology (United Kingdom)Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen
2018, Journal of Scleroderma and Related Disorders
- ☆
The authors declare no conflict of interest.
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.